The Power of Data Analytics Strategy
The report highlights how integrating AI-driven data analytics and automated workflows in pharmaceutical labs can accelerate decision-making, improve data quality, overcome system integration challenges, demonstrate ROI of lab software, and enhance efficiency through effective change management.
Unlock the Value of Data and Workflow Automation in the Lab
This report offers an update on the power of solid data analytics strategy and automated workflow solutions as scientists aim to break down the barriers to the ‘lab of the future’.
“By combining artificial intelligence (AI) and automatic collection of data at scale, pharma companies are able to accelerate their decision making processes and ensure that is based on the highest quality of information.”
— Charles Fracchia, CEO of BioBright & VP of Data at Dotmatics
Key topics covered:
- How to unlock the true value of data and meet the challenges of system integration
- Where ROI of lab software can be evidenced and how to demonstrate value via data
- Why managing changes in the lab environment can benefit efficiency and provide results
Related
About Dotmatics
Dotmatics is a science-driven company with a mission to build the world’s most powerful scientific R&D platform by uniting best-in-class software applications into a flexible, data-driven ecosystem used by over 2 million scientists worldwide, enabling collaboration, automation, and analysis to accelerate innovation and address global challenges in health, environment, and safety.
Data-Driven R&D in Chemicals & Materials: Why an Open Platform is Essential
The webinar titled "Data-Driven R&D in Chemicals & Materials: Why an Open Platform is Essential," presented by Max Petersen of Dotmatics, discusses how a unified, open scientific data platform enhances interoperability among existing R&D IT systems, supports diverse scientific workflows, and empowers researchers in chemicals and materials industries to tackle challenges like sustainability by enabling comprehensive, strategic data access.
Data Evolution in Pharma: The Spread of Multimodal
The pharmaceutical industry is shifting from single-mode to multimodal drug discovery, incorporating diverse therapeutic modalities like biologics, gene therapies, and small molecules, but this evolution presents significant challenges in integrating heterogeneous R&D data and technologies, necessitating advanced, compatible platforms to enable efficient collaboration and leverage AI-driven insights for faster, cost-effective drug development.
Simplify your laboratory workflow management with Dotmatics
Dotmatics offers a unified scientific R&D platform that streamlines laboratory workflow management by integrating various scientific applications, automating data extraction, cleaning, and harmonization into FAIR formats, thereby reducing manual data handling, enhancing collaboration, and accelerating the R&D cycle to help life sciences organizations bring new therapies to market faster.
Prioritizing Data Integrity in R&D: Challenges and Best Practices
The article emphasizes the critical importance of maintaining data integrity in R&D by implementing robust data governance, security, and management practices throughout the research lifecycle to ensure data accuracy, protect patient safety, uphold product efficacy, and comply with regulatory standards amid increasing digitization and evolving threats.
The Rise of Biotech: Why Smaller Companies Are Outpacing Big Pharma on Innovation
Smaller biotech companies are increasingly outpacing big pharmaceutical firms in new molecular entity approvals due to their greater agility, willingness to take risks, and freedom to innovate despite funding challenges, with over half of upcoming blockbuster drug launches expected from first-time launchers who face higher risks but also potential for significant success.